Jan 14, 2021 / 02:00PM GMT
Paola Barbarino -
Good morning, good afternoon, good evening, everybody. Thank you very much for joining us in the first webinar of our series of webinars for 2021. And boy, was the webinar we have was the first one, we have decided this time to tackle one of the most interesting issues in our field and area. We have invited Biogen to present that data on aducanumab.
Now I'm going to tell you a little bit more about what we're going to speak about in the second slide and why we called this webinar. So Biogen, as many of you will know, is a multinational biotechnology company based in the U.S., which specializes in therapies for the treatment of neurological diseases. ADI has worked with Biogen for a number of years. They are interested, of course, in the fact that our membership includes the people that would be eventually beneficiary of what they are doing.
We will hear from Biogen about the data from the Phase III clinical studies ENGAGE and EMERGE. But let me tell you a bit why we did this. Back in November, Biogen presented aducanumab for approval to the Food and Drug Administration in the U
Biogen Inc Corporate Call Transcript
Jan 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers